Cydcor Earns Prestigious DIRECTV Dealer of the Year Revolution Award for the 9th Consecutive Year
Cydcor demonstrates consistent excellence as it receives client top honors
Agoura Hills, California--(Newsfile Corp. - June 11, 2025) - Cydcor, the leading provider of outsourced sales solutions, has once again proven its ability to get results by earning DIRECTV's Revolution Award as Dealer of the Year for the ninth consecutive year. This prestigious recognition is evidence of Cydcor's exceptional sales performance and highlights the company's commitment to consistently delivering outstanding results for its clients. Furthermore, Cydcor was recognized as DIRECTV's top performer in sales, quality, and retention categories.
Cydcor Dealer of the Year 9x
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10205/255304_87b872e074528971_001full.jpg
"At Cydcor, we measure success by the impact we make and the relationships we build. Our commitment to WOWing clients is grounded in our unwavering focus on sales, quality, and retention-the pillars that anchor our efforts," said Cydcor President & CEO Vera Quinn. "Being named DIRECTV Dealer of the Year for the ninth consecutive year is a testament to the dedication of our entire organization, especially our incredible sales network, and the high standards we uphold in every interaction."
DIRECTV, Assistant Vice President Eric King, also commented on Cydcor's sales excellence, saying, "Cydcor continues to execute with excellence and reaches new milestones each year. Our collaboration with their team continues to yield outstanding results as we see great quality and alignment on our platform objectives."
Cydcor remains dedicated to its core values of integrity, excellence, and teamwork. The company is committed to providing its clients with innovative solutions that drive growth and deliver tangible results, and it is proud to have earned the trust and loyalty of its partners.
For three decades and counting, Cydcor has provided customer acquisition solutions to Fortune 500 and emerging companies in a wide range of industries. Cydcor has mastered the power of building relationships with consumers while harnessing technology to acquire, grow, and retain customers for its clients. Founded in 1994, the privately held company is based in Agoura Hills, California. For more information about Cydcor, visit www.cydcor.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies
DelveInsight's, 'Nonalcoholic Steatohepatitis Pipeline Insight, 2025' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight's comprehensive report today! @ NASH Pipeline Outlook Key Takeaways from the NASH Pipeline Report In May 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period. In May 2025, Akero Therapeutics Inc. conducted a phase 2b study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH). DelveInsight's NASH Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for NASH treatment. The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs NASH Emerging Drugs Profile Lanifibranor: Inventiva Pharma Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH. MSDC-0602K: Cirius Therapeutics MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH. TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH. HTD 1801: HighTide Biopharma The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The NASH Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment. NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight's detailed report now! @ New NASH Drugs NASH Companies Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical NASH Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight's expert analysis @ NASH Market Drivers and Barriers Scope of the NASH Pipeline Report Coverage- Global NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Nonalcoholic Steatohepatitis: Overview Pipeline Therapeutics Therapeutic Assessment Nonalcoholic Steatohepatitis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Lanifibranor: Inventiva Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) TERN-501: Terns Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) LY3849891: Eli Lilly and Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name : Company name Drug profiles in the detailed report….. Inactive Products Nonalcoholic Steatohepatitis Key Companies Nonalcoholic Steatohepatitis Key Products Nonalcoholic Steatohepatitis- Unmet Needs Nonalcoholic Steatohepatitis- Market Drivers and Barriers Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion Nonalcoholic Steatohepatitis Analyst Views Nonalcoholic Steatohepatitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
2 hours ago
- Globe and Mail
Health Data Interoperability Market to Hit US$352.13 Billion by 2032 with 22.65% CAGR
According to a recent report by Coherent Market Insights, the global Health Data Interoperability Market is estimated to be valued at USD 84.58 billion in 2025 and is expected to reach USD 352.13 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.65% from 2025 to 2032. The strong growth of the market is driven by the rising demand for seamless data exchange among healthcare providers, the pursuit of enhanced patient care, and the growing adoption of electronic health records (EHRs) and other digital health technologies. Global Health Data Interoperability Market Key Takeaways According to Coherent Market Insights (CMI), the global health data operability care market size is projected to grow more than 4.1X, increasing from USD 84.58 Bn in 2025 to USD 352.13 Bn by 2032, at a CAGR of 22.65%. By deployment model, cloud-based segment is expected to account for nearly two-thirds of the global health data interoperability market share in 2025. Based on component, software category is anticipated to generate a market revenue of about USD 45.92 Bn in 2025. By type, electronic health records (EHRs) segment will likely account for more than two-fifths of the global market revenue share by 2025. North America is expected to retain its monopoly in the global market due to increasing adoption of digital health technologies. As per Coherent Market Insights' latest health data interoperability market research, North America will hold nearly 2/5 of the global market share in 2025. Asia Pacific health data interoperability market is estimated to be valued at around USD 25.62 Bn in 2025. Growing Adoption of Electronic Health Records (EHRs) Boosting Market Growth Coherent Market Insights' new health data interoperability market analysis offers insights into prominent factors driving industry growth. Increasing adoption of electronic health records (EHRs) is one key growth driver. In the contemporary world, more and more hospitals and clinics are embracing electronic health records. For instance, as per the National Center for Health Statistics, about 88.2% of office-based physicians in the United States use an EMR/EHR system. High adoption of EHRs is creating an urgent need for seamless data exchange across various healthcare systems. This will drive demand for health data interoperability solutions during the forecast period. High Implementation Cost and Lack of Standardization Limiting Market Growth The future health data interoperability market outlook looks promising. However, lack of universal standards and high implementation costs are expected to restrain market growth to some extent. Different healthcare providers often use disparate EHR systems, making seamless data exchange challenging. Absence of universally accepted interoperability standards across regions can hinder consistent integration and data sharing, negatively affecting the health data interoperability market growth. Implementing interoperable systems requires substantial investments in both infrastructure and software. This deters smaller clinics and healthcare providers, especially across underserved regions, from opting for these systems, thereby reducing the health data interoperability market demand. Purchase Now Up to 25% Discount on This Premium Research Report: Rapid Shift Towards Value-Based Care to Create Lucrative Growth Avenues Growing adoption of value-based care (VBC) models is driving demand for improved patient outcomes and cost efficiency across healthcare systems. This transition necessitates seamless health data interoperability to enable coordinated care as well as real-time data exchange and performance measurement. As a result, the shift towards VBC is unlocking significant growth opportunities for health data interoperability companies. Policies like HITECH Act and EU GDPR mandate interoperability as well as patient access to data. They will also create lucrative growth prospects for health data interoperability solution providers in the coming years. Policies like the HITECH Act and the EU GDPR emphasize interoperability as well as patient access to health data. These regulations are expected to drive demand for health data interoperability solutions, creating lucrative growth opportunities for industry players. Impact of AI on the Health Data Interoperability Market AI is revolutionizing the health data interoperability industry by tackling long-standing challenges like fragmented data and inconsistent data standards. Organizations use machine learning and NLP to automate data mapping, convert unstructured records into structured formats, and streamline EHR integration. AI-driven predictive analytics can forecast data exchange needs, enhance real‑time clinical workflows, and reduce clinical errors. Federated learning frameworks allow AI models to train across multiple organizations without moving sensitive patient data, which improves privacy and fosters collaboration. AI-powered interoperability solutions are gaining immense traction in the modern healthcare ecosystem. This is due to their potential to boost operational efficiency, enable personalized care, reduce costs, and accelerate the transition towards value‑based models. Emerging Health Data Interoperability Market Trends Rising demand for patient-centric care is a key growth-shaping trend in the market. Today, patients want access to their health information through mobile apps and patient portals. This is creating a need for connected systems. Growing popularity of cloud-based interoperability solutions is expected to boost the overall health data interoperability market value. These scalable and cost-effective platforms are gradually replacing on-premise systems across various regions. Rise of telehealth services and adoption of remote patient monitoring devices are also positively impacting the health data interoperability market growth. These technologies require robust interoperability solutions to ensure seamless data flow between patients, healthcare providers, and monitoring platforms. Analyst's View 'The global health data interoperability market is poised to exhibit robust growth, owing to increasing government mandates and regulatory frameworks, widespread adoption of electronic health and medical record systems (EHR/EMR), and a growing emphasis on value-based care models,' said senior analyst Komal Dighe. Current Events and Their Impact on the Health Data Interoperability Market Event Description and Impact U.S. HTI-1 Final Rule Description: U.S. HTI-1 Final Rule enforces FHIR-based standards for certified health IT systems. Impact: This drives adoption of compliant interoperability platforms and APIs, leading to market growth. EU's European Health Data Space (EHDS) Rollout Description: European Union's EHDS initiative, officially implemented in 2025, requires member states to adopt standardized cross-border health data sharing through unified interoperability frameworks. Impact: This is driving health IT vendors to comply with EHDS standards as well as boosting demand for FHIR-based platforms and multilingual data exchange solutions. Competitor Insights Key companies in health data interoperability market report include: - Cerner Corporation - Epic Systems Corporation - Meditech - Allscripts Healthcare Solutions - athenahealth - InterSystems Corporation - Philips Healthcare - GE Healthcare - Oracle Health Sciences - NextGen Healthcare - IBM Watson Health - Microsoft Health - McKesson Corporation - Siemens Healthineers - Infor Healthcare Key Developments In March 2025, 1upHealth sets a new benchmark for health data interoperability with the launch of its new 1up Platform. The new platform, built on a modern lakehouse architecture, is designed to deliver 'Health Data On Demand'. It offers real-time data access, scalable management, and advanced analytics to help healthcare organizations enhance operational efficiency, care quality, and patient outcomes. In March 2025, Epic Systems Corporation unveiled industry-leading Genomics, AI, and interoperability solutions at the HIMSS 2025 Conference. These new solutions are designed to help healthcare organizations advance in rapidly evolving environment. They have the potential to enhance clinical care, streamline operations, and foster more personalized patient treatments. In January 2025, MEDITECH unveiled its new set of APIs fully compatible with version 4 of the United States Core Data for Interoperability (USCDI v4). This new launch highlights the company's leadership in advancing standards-based interoperability across healthcare systems. Market Segmentation Deployment Model Insights Cloud-Based On-Premises Component Insights Hardware Software Services Type Insights Electronic Health Records (EHR) Health Information Exchange (HIE) Interoperability Solutions Integration Platforms Interoperability Level Insights Foundational Interoperability Structural Interoperability Semantic Interoperability End User Insights Healthcare Providers Healthcare Payers Pharmaceutical Companies Research Institutions Regional Insights North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa § Central Africa Get Customization on this Report: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Raj Shah Email: Send Email Phone: +1-252-477-1362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States City: Burlingame State: California Country: United States Website:
Globe and Mail
2 hours ago
- Globe and Mail
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
[content-module:CompanyOverview|NASDAQ:TSLA] When a stock climbs 14% in just two trading sessions despite getting hit with not one but two analyst downgrades, the market is sending a clear message. Tesla Inc (NASDAQ: TSLA) has done exactly that this week, shrugging off downgrades from both Baird and Argus Research as if they were minor speed bumps on a highway. For growth-focused investors, this apparent disconnect between Wall Street caution and actual market action represents something we love to see and write about: a buying opportunity. The Downgrades That Missed the Mark Monday brought a double dose of analyst pessimism when Baird cut Tesla from Buy to Hold, followed by Argus Research, who made the same move. Both firms cited the same primary concern: the very recent and very public spat between Elon Musk and President Trump, which they believe introduces significant uncertainty to Tesla's prospects. Baird's team also expressed particular skepticism about management's optimistic robotaxi timeline and suggested that positive expectations around the upcoming affordable vehicle launch, which we highlighted last week, might already be baked into the current share price. Meanwhile, Argus focused heavily on how the Musk-Trump dispute could weaken demand, especially as EV tax credits face potential expiration. They warned that Tesla's stock now appears driven more by non-fundamental events than actual business performance. Market Defiance Tells the Real Story But here's what makes Tesla so compelling as a stock to own: Tesla shares have actually gained 14% this week already, suggesting investors are treating the analyst caution as temporary noise rather than a very red warning sign. The stock's ability to climb despite fresh negative coverage indicates that the market sees through the political theater the underlying business momentum and long-term potential. After all, Tesla had posted what analysts called a fundamentally poor quarter in April, yet shares had already begun recovering before the Trump-Musk tensions erupted. That recovery trajectory appears to be reasserting itself regardless of Wall Street's newfound caution. The Bullish Chorus Remains Intact [content-module:Forecast|NASDAQ:TSLA] While Baird and Argus stepped to the sidelines, the broader analyst community tells a different story and is worth noting. The team at Piper Sandler actually reiterated their Overweight rating on Tuesday, echoing the updates from Morgan Stanley and Wedbush this month, already in maintaining bullish stances. Wedbush has been particularly aggressive, slapping a $500 price target on the stock and standing firm despite the recent volatility. This split in analyst opinion actually strengthens the contrarian case. When selective downgrades occur against a backdrop of maintained Buy ratings from other respected firms, it often signals that the negative factors are temporary rather than structural. Case in point: the fact that these downgrades focus primarily on political uncertainty rather than fundamental business deterioration supports this view. Perfect Storm for Patient Capital Tesla's current situation creates an almost textbook setup for contrarian investors. The stock has already absorbed a 25% hit from political noise, endured two high-profile downgrades, and still managed to surge 14% in just two sessions. This combination suggests that temporary headwinds are actually creating opportunity rather than risk. Consider this: if Tesla can gain 14% while dealing with two rare analyst downgrades and political uncertainty, imagine the potential upside once these temporary factors fade. The upcoming affordable vehicle launch and robotaxi development remain on track regardless of Washington drama, and Tesla's core EV market position continues to strengthen globally. For investors who believe in Tesla's long-term transformation story, the current moment offers something increasingly scarce: the chance to buy into a high-growth stock at a potential discount. The Window Is Already Narrowing All that being said, the market's quick dismissal of Monday's downgrades suggests this buying opportunity may be short-lived. Political tensions have a way of resolving themselves, especially when business interests are at stake. Meanwhile, Tesla's product roadmap and market expansion continue regardless of Twitter feuds or analyst hand-wringing. For investors willing to look past the headline noise, these rare downgrades may prove to be perfectly timed entry points rather than warning signals. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...
